Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 20/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5235898 | 0.88 | MET (0.67) | MET | |
| SCHEMBL5228737 | 0.88 | MET (0.66) | MET | |
| SCHEMBL5228728 | 0.81 | MET (1.00) | MET | |
| SCHEMBL5226227 | 0.76 | MET (0.69) | MET | |
| SCHEMBL5231901 | 0.76 | MET (0.69) | MET | |
| SCHEMBL9910362 | 0.75 | MET (1.00) | MET | |
| SCHEMBL11511924 | 0.72 | NPC1 (0.43) | MET | |
| SCHEMBL5229478 | 0.69 | MET (1.00) | MET | |
| SCHEMBL6086981 | 0.68 | MET (1.00) | MET | |
| SCHEMBL5234066 | 0.68 | MET (1.00) | MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1644377-A4 | TRIAZOLOTRIAZINE COMPOUNDS AND USES THEREOF | SUGEN INC (US) | 2007-09-05 | — | — | EP | disclosed |
| US-7122548-B2 | Triazolotriazine compounds and uses thereof | SUGEN, INC. (US) | 2006-10-17 | — | — | US | disclosed |
| EP-1644377-A1 | TRIAZOLOTRIAZINE COMPOUNDS AND USES THEREOF | Sugen, Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20050075340-A1 | Triazolotriazine compounds and uses thereof | SUGEN, INC. | 2005-04-07 | — | — | US | disclosed |
| WO-2005010005-A1 | TRIAZOLOTRIAZINE COMPOUNDS AND USES THEREOF | SUGEN, INC. (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075340-A1 | Triazolotriazine compounds and uses thereof | MET, TPMT, RET | MET 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.